The Medical Advisor

An evidence‑aware guide to off‑label cancer therapies, integrative oncology, and emerging research — without hype or false promises. This page serves as the central hub for OneDayMD’s coverage of repurposed drugs in cancer care, integrating conventional oncology standards with systems biology, real‑world data, and ethical analysis. What This Hub Covers (Quick Overview) This hub explains: What repurposed drugs are — and what they are not. Which drugs show credible anti‑cancer signals vs speculation. How repurposed therapies may (or may not) integrate with standard oncology. The evidence hierarchy used across OneDayMD. Safety, ethics, and regulatory realities. It is designed for patients, clinicians, and researchers seeking clarity rather than promotion . Diverse cancer hallmarks targeted by repurposed non-oncology drugs. This figure was created with Biorender.com. Source:  Nature 2024 Executive Summary Repurposed drugs in cancer care refer to existing, FDA‑approved medications or...

Breast cancer remains one of the most challenging and prevalent malignancies worldwide, with metastatic and treatment-resistant cases posing significant therapeutic hurdles. Conventional treatment options, including chemotherapy, targeted therapies, and immunotherapy, often reach their limits, particularly in advanced stages such as triple-negative breast cancer (TNBC).  For patients with actionable mutations identified through molecular profiling, targeted therapies are the preferred treatment approach. In particular, for estrogen receptor–positive (ER+) breast cancer patients with a low Oncotype DX recurrence score, hormonal therapy alone is often appropriate, as genomic testing indicates a low risk of cancer recurrence and supports de-escalation of more aggressive systemic treatments. The preference for targeted treatments reflects their demonstrated efficacy in improving outcomes in these molecularly defined subgroups, underscoring the importance of comprehensive genomic profil...